G1 Therapeutics Inc (GTHX) Position Boosted by Swiss National Bank
Swiss National Bank lifted its stake in G1 Therapeutics Inc (NASDAQ:GTHX) by 4.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 37,100 shares of the company’s stock after purchasing an additional 1,600 shares during the quarter. Swiss National Bank owned 0.11% of G1 Therapeutics worth $1,940,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can boosted its position in shares of G1 Therapeutics by 148.3% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after purchasing an additional 1,560 shares during the period. Strs Ohio boosted its position in G1 Therapeutics by 78.3% during the 2nd quarter. Strs Ohio now owns 4,100 shares of the company’s stock worth $178,000 after acquiring an additional 1,800 shares during the period. WINTON GROUP Ltd acquired a new stake in G1 Therapeutics during the 3rd quarter worth about $218,000. Metropolitan Life Insurance Co. NY boosted its position in G1 Therapeutics by 48.4% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 6,818 shares of the company’s stock worth $296,000 after acquiring an additional 2,224 shares during the period. Finally, State Board of Administration of Florida Retirement System acquired a new stake in G1 Therapeutics during the 2nd quarter worth about $317,000. Institutional investors and hedge funds own 71.02% of the company’s stock.
In other news, Director Seth Rudnick sold 10,000 shares of the firm’s stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $49.72, for a total transaction of $497,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Terry L. Murdock sold 3,519 shares of the firm’s stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $49.18, for a total value of $173,064.42. The disclosure for this sale can be found here. Insiders have sold a total of 59,613 shares of company stock valued at $2,631,874 over the last ninety days. Company insiders own 15.92% of the company’s stock.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.59) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.08. Equities analysts predict that G1 Therapeutics Inc will post -2.49 earnings per share for the current fiscal year.
A number of equities research analysts have commented on GTHX shares. Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 8th. Cowen restated a “buy” rating on shares of G1 Therapeutics in a research report on Thursday, August 9th. JPMorgan Chase & Co. raised their price objective on G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday, August 10th. BTIG Research started coverage on G1 Therapeutics in a research report on Monday, September 10th. They set a “buy” rating and a $80.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $79.00 price objective on shares of G1 Therapeutics in a research report on Monday, September 17th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $74.00.
WARNING: “G1 Therapeutics Inc (GTHX) Position Boosted by Swiss National Bank” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/g1-therapeutics-inc-gthx-position-boosted-by-swiss-national-bank/2662720.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Featured Story: Technical Analysis
Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics Inc (NASDAQ:GTHX).
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.